Abstract The identification of molecular features that contribute to the progression of breast cancer can provide valuable insight into the pathogenesis of this disease. Deregulated microRNA expression represents one type of molecular event that has been associated with many different human cancers. In order to identify a miRNA/mRNA regulatory interaction that is biologically relevant to the triple-negative breast cancer genotype/phenotype, we initially conducted a miRNA profiling experiment to detect differentially expressed miRNAs in cell line models representing triple-negative (MDA-MB-231), ER ? (MCF7), and HER-2 overexpressed (SK-BR-3) histotypes. We identified human miR-34a expression as being [3-fold down (from its median expression value across all cell lines) in MDA-MB-231 cells, and identified AXL as a putative mRNA target using multiple miRNA/target prediction algorithms. The miR-34a/AXL interaction was functionally characterized through ectopic overexpression experiments with a miR-34a mimic in two independent triple-negative breast cancer cell lines. In reporter assays, miR-34a binds to its putative target site within the AXL 3 0 UTR to inhibit luciferase expression. We also observed degradation of AXL mRNA and decreased AXL protein levels, as well as cell signaling effects on AKT phosphorylation and phenotypic effects on cell migration. Finally, we present an inverse correlative trend in miR-34a and AXL expression for both cell line and patient tumor samples.
Introduction
Triple-negative tumors of the breast represent a unique subgroup of an otherwise heterogeneous disease that accounts for 10-25% of all the reported breast cancer cases [1, 2] . These tumors lack the expression of the steroid hormone receptors estrogen and progesterone, and have decreased expression of ErbB-2/human epidermal growth factor receptor 2 (HER-2). In molecular studies that classified breast cancer tumors and cell lines based on global gene expression profiles, most triple-negative samples were representative of the basal B subtype as they expressed markers characteristic of the underlying basal (myoepithelial) layer of cells in breast ducts [3] [4] [5] [6] [7] [8] [9] . Triple-negative tumors generally display aggressive metastatic behavior, have a high propensity for recurrence, and are associated with poor patient survival [10] . Premenopausal women of African, African-American, and Hispanic ethnicity have a higher rate of risk for this disease [11] . Although systemic, neoadjuvant chemotherapy has been a viable therapeutic option in some metastatic cases, molecular-targeted therapies having any degree of measured success are currently unavailable.
MicroRNAs represent a novel, conserved class of endogenous non-coding RNAs that negatively regulate gene expression via the RNA interference (RNAi) pathway [12] . A variety of biological processes have been implicated as being regulated by miRNAs including cell development, differentiation, proliferation, metabolism, and the stress response (for reviews see [13] [14] [15] [16] ). It is now recognized that many miRNAs reside in regions of genomic instability associated with cancer, and that genetic rearrangements, gain or loss in DNA copy number, errors in miRNA processing, epigenetic regulation of miRNA expression, and activation by oncogenic transcription factors may all lead to aberrant miRNA expression [17] . MicroRNAs can function as either oncogenes or tumor suppressors depending on their level of expression and the biological function of their targeted transcript. For instance, oncogenic miRNAs promote tumorigenesis when they are overexpressed and negatively regulate genes whose products are involved in cell-cycle arrest and apoptosis [18] . Conversely, miRNAs with tumor suppressor roles are often downregulated resulting in an inability to regulate cell growth and proliferation as a result of their absence [19] . To date, there are [1,000 mature human miRNAs that have been identified, yet the vast majority of mRNA targets (each miRNA is estimated to regulate multiple if not hundreds of mRNA transcripts) remain uncharacterized [12] .
The aim of this study was to identify and characterize a novel miRNA/mRNA target interaction that is relevant to the molecular biology and/or pathophysiology of triplenegative breast cancer. We find the downregulated expression of human miR-34a to be reciprocally linked to increased AXL mRNA and protein expression in triplenegative breast cancer cell lines with an invasive phenotype. AXL is a member of the TAM (Tyro3, AXL, and MER) receptor tyrosine kinase family and its signaling plays a diverse role in cellular processes including survival, proliferation, migration, invasion, angiogenesis, autophagy, platelet aggregation, and natural killer-cell differentiation [20] . High AXL expression was recently shown to be a negative prognostic indicator for survival in breast cancer patients [21] . Using two independent triple-negative breast cancer cell lines, we show that the ectopic overexpression of miR-34a results in decreased AXL mRNA and protein levels, decreased cell migration potential, and decreased phospho-AKT protein expression levels (MDA-MB-231 cells), without having any significant concomitant effect on the viability or induction of apoptosis in these cell lines. AXL is the second receptor tyrosine kinase (c-MET being the first [22] [23] [24] [25] [26] [27] ) identified as being regulated by miR-34a. ; colorectal cell lines SW480 and SW620; and the renal cell line SN12C were maintained in RPMI 1640 basal medium supplemented with 10% v/v heat-inactivated fetal bovine serum (Invitrogen; Carlsbad, CA). The immortal nontumorigenic breast cell line MCF10A (ER -/PR -/HER-2 -) was maintained in DMEM/F12 basal medium supplemented with 5% v/v horse serum (Invitrogen; Carlsbad, CA), 20 ng/ml final epidermal growth factor, 0.5 lg/ml final hydrocortisone, 100 ng/ml final cholera toxin, and 10 lg/ml final insulin (all from Sigma-Aldrich, St. Louis, MO). Antibiotics were excluded from all the media. Cells were grown at 37°C with 5% CO 2 and passaged every 3-4 days for up to 10 generations. MCF10A and MDA-MB-231 cells were obtained from ATCC (Manassas, VA; 2008). MCF7, SK-BR-3, SN12C, and HeLa cells were obtained from the NCI Developmental Therapeutics Program, NCI, and NIH (Bethesda, MD; 2008). Hs578T, BT549, and T47D cells were gifted by Dr. Stan Lipkowitz (NCI, NIH, Bethesda, MD; 2008). SW480 and SW620 cells were gifted by Dr. Thomas Reid (NCI, NIH, Bethesda, MD; 2009). All cell lines tested negative for mycoplasma contamination using the MycoAlertÒ Mycoplasma Detection Kit with a Lucetta TM Luminometer (Lonza Rockland, Inc.; Rockland, ME).
Materials and methods

Cell lines
Tissue collection
Fresh-frozen tumor specimens were obtained at time of surgery from breast cancer patients, as described previously [28] . Patients were recruited, who signed letters of consent at hospitals in Baltimore, Maryland, USA, between 1993 and 2003. Clinical and pathological information was obtained from medical records and pathology reports. Disease staging was performed according to the tumornode-metastasis (TNM) system of the American Joint Committee on Cancer/the Union Internationale Contre le Cancer (AJCC/UICC). The Nottingham system was used for determining the tumor grade. The protocol for collection of tumor specimens, survey data, and clinical as well as pathological information was reviewed and approved by the University of Maryland Institutional Review Board (UMD protocol #0298229). IRB approval of this protocol was then obtained for all participating institutions (Veterans Affairs Medical Center, Union Memorial Hospital, Mercy Medical Center, and Sinai Hospital). The research was also reviewed and approved by the NIH Office of Human Subjects Research.
Immunohistochemical characterization of basal-like breast cancer Basal-like breast tumors were identified by immunohistochemistry for estrogen receptor (ER), HER-2 receptor, EGFR receptor, and cytokeratin 5/6 using the following antibodies: ready-to-use monoclonal (Clone 6F11) antibody (Ventana Medical Systems; Tucson, AZ) for estrogen receptor; 1:100 diluted rabbit polyclonal antibody (Dako North America, Inc.; Carpinteria, CA) for HER-2; readyto-use mouse antibody for EGFR; and 1:250 diluted mouse monoclonal antibody for cytokeratin 5 (Lab Vision Corporation; Fremont, CA). Basal-like breast tumors were ER negative, HER-2 negative, and either EGFR positive or cytokeratin 5/6 positive, as described previously [29] . Aberrant nuclear p53 expression was determined using a 1:100 diluted monoclonal DO-7 antibody (Dako North America, Inc.; Carpinteria, CA). A tumor was scored p53-positive if more than 10% of the cancer cells showed nuclear positivity for p53 protein expression. Tumors were screened for p53 mutations as previously described [30] .
MicroRNA expression profiling
The small RNA (sRNA) fractions from four separate passages (biological replicates) of MCF7, SK-BR-3, MDA-MB-231, and MCF10A cells were extracted using Qiagen's miRNeasy kit following the manufacturer's instructions (Qiagen; Germantown, MD). Five micrograms of sRNA was labeled with either Cy3 (MCF10A) or Cy5 (breast cancer cell) fluorescent label (GE Healthcare; Piscataway, NJ) using the mirVana miRNA labeling kit (Ambion; Austin, TX). The labeled products were hybridized to miRVana miRNA Bioarrays V2 (Ambion, Austin, TX) and washed following the manufacturer's protocol. Each array was composed of 328 human miRNA probes in addition to 114 mouse and 46 rat miRNAs. The comparative hybridization for each breast cancer cell line to the reference MCF10A cell line control was conducted in quadruplicate (n = 12 total arrays). Processed arrays were scanned for dual channel hybridization using a GenePix 4000B scanner (Molecular Devices; Sunnyvale, CA). Analyses were performed using BRB-Array Tools Version 3.8.1 (http://linus.nci.nih.gov/BRB-ArrayTools.html). Replicate spots for each miRNA were averaged within the array, background adjusted, and log 2 normalized. Normalization was performed using a per chip median normalization method. Only those miRNAs with at least a threefold change in expression from its median value in 4 of 12 total arrays were retained. Samples and genes were subjected to a hierarchical cluster analysis with average linkage under the Euclidian distance similarity metric using the Cluster 3.0 (http://rana.stanford.edu/software) and Java TreeView 1.1.4r3 [31] applications. MiRNA probes of mouse, rat, and the manufacturer's (Ambion) origins that passed the gene filter were excluded from future analyses. Microarray expression data are available at the Gene Expression Omnibus (GEO) (accession GSE21834) and are in accordance with MIAME guidelines.
MicroRNA-target predictions
In a PAM analysis of global gene expression array data conducted on 51 breast cancer cell lines, 305 genes were identified as classifiers for the luminal, basal A, and basal B subtypes based on a threshold scaling of 2.8 [6] . From this list, 20 genes (the top 10 highest and lowest scores for the basal B subtype, excluding multiple probes for the same gene) were used in three separate miRNA target prediction searches (TargetScanHuman 5.1, http://www.targetscan. org/; Microcosm Targets 5, http://www.ebi.ac.uk/enrightsrv/microcosm/htdocs/targets/v5/; and MiRanda 2008, http://www.microrna.org/microrna/home.do) to identify putative miRNA regulators from the list of 34 differentially expressed miRNAs observed in our profiling experiment. For MDA-MB-231 cells, only those predicted miRNAs that matched with the 20 genes from the classifier list and exhibited an inverse relationship in expression to the classifier genes were considered.
Northern hybridization
Total RNA (10 lg) was resolved on a 15% TBE-Urea gel (1.0-mm thickness) (Invitrogen; Carlsbad, CA), electroblotted onto a positively charged nylon membrane (Roche Diagnostics, Indianapolis, IN), and UV crosslinked at 120,000 lJoules using a UV Stratalinker 1800 (Agilent Technologies; Santa Clara, CA Quantitative real-time PCR Total RNA was prepared from cell lines using the miRNeasy extraction kit (Qiagen; Germantown, MD). Singlestranded cDNA was synthesized from 100 ng total RNA using the TaqManÒ MicroRNA Reverse Transcription kit (Applied Biosystems; Foster City, CA). QRT-PCR was performed on an ABI 7900HT Sequence Detection System using a human miR-34a microRNA TaqManÒ Expression Assay and TaqManÒ Universal PCR Master Mix (Applied Biosystems; Foster City, CA). The small nucleolar RNA molecule RNU48 was used as an endogenous control for normalization, as it displayed the lowest variance in threshold cycle times (C t ) compared to seven other controls tested across all 10 cell lines. Relative miR-34a expression was determined by the comparative C T method. Three biological replicates for each individual cell line were tested and PCR amplifications were performed in triplicate for each sample. The threshold cycle times were averaged across all technical and biological replicates within a given cell line. Fold difference in miR-34a expression for each cell line relative to the MCF10A cell line was calculated using the equation 2 -DDCt . Error bars for the fold-difference calculations represent the range in DDC t values based on the incorporation of the standard deviations for this value.
For the analysis of patient tumor samples, total RNA from 26 histologically characterized triple-negative breast cancer samples were used in measuring miR-34a and AXL expression levels. In brief, total RNA from fresh-frozen breast tissue sample biopsies was isolated using TRIzol reagent according to the manufacturer's instructions (Invitrogen; Carlsbad, CA). The concentration of each RNA sample was measured using a NanoDrop spectrophotometer (NanoDrop Technologies; Wilmington, DE), and the RNA integrity was confirmed with an Agilent 2100 Bioanalyzer (Agilent Technologies; Palo Alto, CA). AXL expression was measured from cDNA synthesized from 1 lg total RNA using the High Capacity RNA-to-cDNA kit, Gene Expression Primer Assays, and TaqManÒ Gene Expression Master Mix (Applied Biosystems; Foster City, CA). ACTB mRNA expression was used for normalization.
Both miR-34a and RNU48 were measured from each sample as previously described for cell lines.
Construction of luciferase expression vectors
Complementary oligonucleotides (48 bp) spanning the putative miR-34a-binding site in the 3 0 UTR of AXL were synthesized with XhoI compatible ends. Wild type (WT) and mutant sequences representing changes in the seed sequence-binding region of the AXL 3 0 UTR at positions 2 (M2), 3 (M3), 2 and 4 (M2/4), or 3 and 5 (M3/5) relative to the 5 0 end of the miRNA are listed in Online Resource Table 1 . Following heat denaturation in HEPES buffer, the synthetic forward and reverse oligonucleotides were annealed at 37°C. The annealed inserts were phosphorylated at 37°C using T4 DNA Kinase and ATP. The pMIR-GLO Dual-Luciferase miRNA Target Expression Vector (Promega; Madison, WI) was prepared for ligation by XhoI digestion followed by BAP treatment of the ends. A threefold excess of insert to vector was used in the ligation reactions with T4 DNA Ligase at 15°C. Recombinant vector plus inserts were transfected into TOP10 cells (Invitrogen; Carlsbad, CA) and plated onto ampicillin selective LB agar plates. Positive clones containing inserts were identified as PCR products using pMIR-GLO vectorspecific primers (Forward: CGCAAGATCCGCGAGA TTCT and Reverse: TAGTTATTGCTCAGCGGTGG). PCR positive clones were then subjected to sequencing to verify the integrity of the insert. Before the luciferase assays, clones were grown and plasmid DNA was purified using a Qiagen Plasmid Mini Kit (Qiagen; Germantown, MD) followed by endotoxin removal with MiraCLEANÒ (Mirus Bio LLC; Madison, WI).
The miTarget TM microRNA 3 0 UTR target sequence expression clone vector containing the full-length 3 0 UTR of AXL insert (GeneCopoeia; Rockville, MD) and a control vector minus insert were transfected into One ShotÒ Stbl3 TM cells (Invitrogen; Carlsbad, CA) and plated onto kanamycin selective LB agar plates. Plasmid DNA from positive clones was purified using a QIAfilter TM Plasmid Midi Kit with endotoxin removal (Qiagen; Germantown, MD).
Luciferase reporter assay
For assays involving the full-length AXL 3 0 UTR, MDA-MB-231 cells (10,000 cells per well) were seeded in a white 96-well CulturPlate TM (PerkinElmer; Waltham, MA) and incubated for 24 h before transfection. The expression vectors (1 lg) were co-transfected with AllStar Negative Control siRNA (siNEG), hsa-miR-34a miScript mimic (UGGCAGUGUCUUAGCUGGUUGU) (34a-mimic), or hsa-miR-200c miScript mimic (UAAUACUGCCGGGU AAUGAUGGA) (200c-mimic) (Qiagen; Germantown, MD) at a 10 nM final concentration using Lipofectamine TM 2000 (Invitrogen; Carlsbad, CA). Both firefly and Renilla luciferase were measured 24-h post-transfection on a FLUOstar OPTIMA microplate reader (BMG Labtech; Cary, NC) using the Luc-Pair TM miR Luciferase Assay system (GeneCopoeia; Rockville, MD). For the wild-type and mutant seed sequence expression constructs (100 ng), both fast kinetic firefly and Renilla luciferase expression was measured 48-h post-transfection in MDA-MB-231 cells (25,000 cells per well) using the Dual-Luciferase Reporter Assay System (Promega; Madison, WI). The mean ± SEM is reported for each transfection condition (n = 3). Significance was determined by a two-tailed unpaired t test for means (siNEG vs. mimic or mimic for WT vs. mimic for mutant construct).
Branched DNA capture assay MDA-MB-231 or Hs578T cells (20,000 cells per well; 96-well plate) were reverse transfected with siNEG, siRNA AXL (siAXL) (TCCAAGATTCTAATGATTAA) (Qiagen; Germantown, MD), or 34a-mimic at a 10 nM final concentration using Lipofectamine TM 2000. Relative AXL mRNA levels in cell lysates were determined 48-h posttransfection using an AXL-specific probeset with the Quantigene Ò branched DNA reagent (1.0) and capture assay system (Panomics; Fremont, CA) (see Martin et al. for assay details [32] ). All transfection experiments were performed in triplicate with a total of 36 measurements per transfection condition. AXL mRNA levels were normalized to corresponding PPIB mRNA levels measured from the same lysate followed by averaging of replicates across experiments. Significance was determined by a two-tailed unpaired t test for means (siNEG treated samples were used as the control for all comparisons).
Western blots
MDA-MB-231 or Hs578T cells (600,000 cells per well; 6-well plate) were reverse transfected with siNEG, siAXL, or 34a-mimic at a 10 nM final concentration using Lipofectamine TM 2000. Transfected cells were washed in PBS and directly lysed within the well by the addition of Cell Extraction Buffer (Invitrogen; Carlsbad, CA) containing 1X Halt TM Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific; Rockford, IL) followed by gentle scraping. After a 30-min incubation on ice, protein lysates were centrifuged at 13,000 rpm for 10 min at 4°C to remove cellular debris. All the protein lysates were harvested 48-h post-transfection. Total protein concentration was measured by the BCA TM protein assay (Thermo Scientific; Rockford, IL). Total cell extracts (5 lg for AXL blots or 10 lg for all other protein blots) were reduced and resolved on a 4-12% Tris-glycine gradient gel (Invitrogen; Carlsbad, CA). Proteins were electroblotted (Tris-glycine transfer buffer ? 10% v/v methanol; 3 h, 25 volts constant) to an Invitrolon TM PVDF membrane (Invitrogen; Carlsbad, CA) and blocked with 5% w/v milk in 19 TBS ? 0.1% v/v Tween-20. For immunodetection, membranes were incubated at 4°C overnight with primary antibodies specific for AXL, phospho-p44/42 ERK1/2 (Thr202/Tyr204), p44/42 ERK1/2, phospho-AKT (Ser473), phospho-AKT (Thr308), AKT (pan), and b-actin (Cell Signaling Technology; Danvers, MA). Beta-actin expression was examined as a loading control. Following washes with 19 TBS ? 0.1% v/v Tween-20, membranes were incubated 1 h with either HRP-linked anti-rabbit or anti-mouse secondary antibody (Cell Signaling Technology; Danvers, MA). Chemiluminescence was detected on film using SuperSignal Ò West Pico Chemiluminescent Substrate (Thermo Scientific; Rockford, IL). Membranes were stripped with Restore TM Plus Western Blot Stripping Buffer (Thermo Scientific; Rockford, IL) in a 30-min incubation at room temperature. The blots were re-blocked in 5% w/v milk, 19 TBS ? 0.1% v/v Tween-20 for 1 h and re-probed. The signal density for each protein was normalized to the respective b-actin band in that sample and expressed as a fraction of the siNEG transfected sample on the blot using ImageJ 1.43 s (http://rsb.info.nih. gov/ij/) software [33] .
For rescue experiments, MDA-MB-231 cells (150,000 cells per well) were seeded in six-well plates and incubated for 24 h before transfection. Using Lipofectamine TM 2000, cells were cotransfected with siNEG, siAXL, or 34a-mimic at a 10 nM final concentration along with either an OmicsLink TM Expression-Ready ORF-cloning vector containing an AXL cDNA (NM_021913) insert that lacks the 3 0 UTR or a control vector with an EGFP insert (2 lg) (GeneCopoeia; Rockville, MD). Twenty-four hours posttransfection, cells were harvested and lysed as previously described.
Cell migration assay MDA-MB-231 or Hs578T cells (20,000 cells per well) were reverse transfected on the surface of a microporous (8.0-lm pore size) PET membrane (BD Falcon TM HTS Insert System, BD Biosciences; San Jose, CA) with siNEG, siAXL, siRNA MET (siMET) (ACCGAGGGAATCAT CATGAAA) (Qiagen; Germantown, MD), or 34a-mimic at a 10 nM final concentration using Lipofectamine TM 2000. Cells were starved 48-h post-transfection by aspirating the growth media and replacing it with serum-free media. After a 24-h starvation, 10% serum-containing media was added to the lower chamber (underside of membrane). Cells were allowed to migrate for 16 h before processing. In brief, cells on the transfection side of the membrane were swabbed and cells on the underside of the membrane were fixed in methanol. Following washes in PBS, cells on the underside of the membrane (migrated cells) were DAPI stained, imaged, and counted using a Discovery-1 Screening System (Molecular Devices; Sunnyvale, CA). All migration assays were performed in triplicate with a total of 10 measurements per transfection condition. Significance was determined by a one-way ANOVA with a Dunnett multiple comparison post-test using siNEG treated samples as the control.
Cell viability/proliferation assay
In parallel with the migration assay, MDA-MB-231 or Hs578T cells (20, Aqueous) (Promega; Madison, WI) was determined after the addition of the reagents 76-h post-transfection. All viability assays were performed in triplicate with a total of 30 measurements per transfection condition for each assay. Significance was determined by a two-tailed unpaired t test for means (siNEG treated samples were used as the control for all comparisons).
Cell-cycle analysis and apoptosis MDA-MB-231 or Hs578T cells (600,000 cells per well; 6-well plate) were reverse transfected with siNEG, siAXL, siMET, or 34a-mimic at a 10 nM final concentration using Lipofectamine TM 2000. After 72 h, cells were washed in DPBS and fixed in 70% ethanol overnight at 4°C. DNA staining was performed with 50 lg/ml propidium iodide and 100U RNAse A for 30 min at 4°C. Data collection was performed on a FACscalibur flow cytometer (BectonDickinson; Franklin Lakes, NJ) with CellQuest Pro software. For each sample, 25,000 events were collected and cell-cycle modeling was performed using FlowJo 9.3 (Tree Star, Inc.; Ashland, OR) software. Aggregated cells were gated out, and the percentages of cells within the different phases of the cell cycle were determined. Flow cytometric measurements were made on transfections performed in triplicate for each condition. Significance was determined by a two-tailed unpaired t test for means (siNEG treated samples were used as the control for all comparisons).
For assessing the effects on cell viability and the possible induction of apoptosis following transfection with miR-34a, Annexin V-PE and PI flow cytometry was conducted. MDA-MB-231 or Hs578T cells were harvested 72 h post-transfection and stained following the manufacturer's instructions for the Annexin V-APC Apoptosis Kit (eBioscience, Inc.; San Diego, CA). Data collection was performed on a FACscalibur flow cytometer (Becton-Dickinson; Franklin Lakes, NJ) using CellQuest Pro software. For each sample, 10,000 events were collected, and apoptotic fractions were determined using FlowJo 9.3 (Tree Star, Inc.; Ashland, OR). Flow cytometric measurements were made on transfections performed in triplicate for each condition. Significance was determined by a two-tailed unpaired t test for means (siNEG treated samples were used as the control for all comparisons).
Statistical analyses
All statistical analyses were performed using GraphPad Prism v5.0c software (GraphPad Software, Inc.; La Jolla, CA).
Results
Differentially expressed miRNAs among three breast cancer cell lines with different histotypes
To identify differentially expressed miRNAs among the breast cancer cell lines that differed in their hormone receptor histotypes, we profiled miRNA expression in cell line models representative of the luminal (MCF7 and SK-BR-3; ER ? /PR ? /HER-2 -and ER -/PR -/HER-2 ? , respectively) and basal B (MDA-MB-231; ER -/PR -/HER-2 -) molecular subtypes, and normalized each profile to that of a common reference sample (MCF10A; normal breast, non-tumorigenic control). Thirty-four miRNAs from a total of 328 human miRNAs (10.4%) spotted on the array passed the threshold of having at least a threefold change in expression in either direction from its median value across all samples/arrays for at least 33% of all arrays tested (Fig. 1a) . Of these 34 miRNAs, 21 (61.8%) were observed to meet this threshold in the MDA-MB-231 cell line alone (with either up or down expression relative to MCF10A cells consistent in at least two of 4 arrays (replicates) that were tested). Interestingly, across the three cell lines, only two of these 21 miRNAs (miR-200b and miR-375) had the same directionality in expression (up in both MDA-MB-231 and SK-BR-3 cell lines relative to MCF10A); indicating that the majority of these miRNAs in MDA-MB-231 cells were inversely expressed in the luminal cell lines. Some of our results are consistent with a previously reported miRNA microarray expression profiling study in breast cancer cell lines [34] . For example, the downregulated expression of miR-141 and 200c (clustered on human chromosome 12) and the upregulated expression of miR-221 and miR-222 (clustered on human chromosome X) in the MDA-MB-231 cell line relative to MCF10A were also observations shared in this study. The correlated upregulation of miR-221 and miR-222 has also recently been confirmed in triple-negative breast cancer patient samples [35] . MB231_2 MB231_2  MB231_3 MB231_3  MB231_4 MB231_4  MCF7_1 MCF7_1  MCF7_3 MCF7_3  MCF7_2 MCF7_2  MCF7_4 MCF7_4  SKBR3_1 SKBR3_1  SKBR3_2 SKBR3_2  SKBR3_3 SKBR3_3  SKBR3_4 SKBR3_4   hsa_miR_146a hsa_miR_146a  hsa_miR_377 hsa_miR_377  hsa_miR_190 hsa_miR_190  hsa_miR_539 hsa_miR_539  hsa_miR_208 Bioinformatic prediction of a miR-34a/AXL interaction is relevant to the basal B molecular subtype in breast cancer cell lines
Previous studies have shown that breast cancer cell lines, as tumor samples, can be grouped into distinct molecular subtypes based on their global gene expression profiles [4, 6] . In a study by Neve et al. [6] , a Prediction Analysis of Microarrays (PAM) that was applied to gene expression data from 51 breast cancer cell lines identified 305 classifiers that would distinguish these cell lines as belonging to either the basal A, B, or luminal subtypes. From this list of classifiers, we focused on those genes specific to the basal B subtype that had the top ten positive and negative PAM scores when applying our target prediction analysis. We chose the basal B subtype because cell lines classified within this group (including MDA-MB-231) are often of the triple-negative histotype, with a characteristic mesenchymal-like appearance, high proliferation rates, and high invasiveness [4, 6] . We used three separate miRNA target prediction algorithms (each of which with weight different parameters in binding and having different levels of predictive power, yet all are confined to the 3 0 UTR of the mRNA) to identify putative interactions between our 34 differentially expressed miRNAs with genes in the basal B gene classifier subset. Only those interactions in which there was an inverse correlation in expression between the miRNA and the mRNA target were considered (Online Resource Table 2 ) for possible follow-up studies. There were six miRNA/mRNA interactions that were identified by all the three-prediction programs: miR-34a/AXL, miR34a/FOSL1, miR-191/TSPAN13, miR-200b/TSPAN13, miR-222/TSPAN13, and miR-200a/FOXA1. We excluded the miR-200a/FOXA1 prediction because the FOXA1 gene was more of a distinguishing classifier for the luminal subtype (both basal A and B subtypes exhibited low expression of FOXA1) and the free energy of binding between miR-200a, and its target site was not as strong as some of the other predicted interactions. Likewise, with regard to the miRNAs targeting TSPAN13, there were only poorly conserved binding sites for these miRNAs across several species, and the free energy of binding for each miRNA was comparatively weak. The putative interactions predicted for miR-34a with either AXL or FOSL1 were much more appealing, as both had highly conserved (across 11 species in the case for AXL) seed sequence matches of eight consecutive nucleotides beginning at the 5 0 end of the miRNA, and strong binding energies (DG = -28.5 and DG = -22.8 or -24.3 kcal/mol for AXL and FOSL1, respectively). Although there are two putative binding sites for miR-34a in the 3 0 UTR of FOSL1 (one site is considered poorly conserved; Online Resource Fig. 1 ), there appears to be an additional stretch of base complementarity (7 nt) following the seed sequence region of miR-34a that is unique to the targeting site within AXL; making this binding interaction stronger with the possibility of a higher probability of occurrence (Fig. 1b) . We focused our next series of experiments on characterizing the possible interaction between miR-34a and the receptor tyrosine kinase AXL, as AXL has been directly associated with a variety of different cancers including those of the breast [21, [36] [37] [38] . Moreover, AXL was shown to play an important role in mediating cell motility and invasiveness in breast cancer cells [38] .
miR-34a expression is significantly downregulated in triple-negative breast cancer cell lines and is inversely related to AXL protein expression To confirm the observed expression levels of miR-34a from our array results, we performed a Northern blot hybridization and qRT-PCR analysis with probes and primers specific for the mature form of miR-34a, respectively, using the same cell lines representative of the array as well as six additional cancer cell lines (Fig. 1c, d ). Mature miR-34a expression was significantly downregulated in triple-negative breast cancer cell lines representative of the basal B subtype (MDA-MB-231, Hs578T, and BT549), but was expressed in the luminal cell lines MCF7, T47D, and HER-2 expressing SK-BR-3 cell line. MDA-MB-231 cells and other triplenegative metastatic breast cancer cell lines express higher than normal levels of the receptor tyrosine kinase AXL [38] [39] [40] (Online Resource Fig. 2) ; high AXL expression being a positive correlate of cell aggressiveness. Interestingly, AXL expression was also high in the renal cancer cell line SN12C and detectable in the colorectal cell lines SW480 and SW620, whereas miR-34a expression in these cell lines was either absent or weakly expressed, respectively. We examined whether decreased mature miR-34a expression in these cell lines could be the result of an error in the cellular processing of the precursor molecule to the mature form of the miRNA. Our qRT-PCR results indicate that the primary transcript for miR-34a is poorly expressed and that this would explain the low levels of both precursor and mature forms of miR-34a in these cells (Online Resource Fig. 3 ). Since miR-34a is known to be under the direct regulatory control of p53 [41] [42] [43] [44] [45] [46] [47] [48] , and mutations in this gene were previously shown to be present in the cell lines we used, miR34a expression might be influenced by the inability of p53 to bind or activate transcription. Alternatively, a recent study has shown that the inactivation of miR-34a transcription could be the direct result of CpG methylation [49] . Given the correlation between low levels of miR-34a expression in cell lines exhibiting high levels of AXL, and the putative target site for miR-34a in the AXL 3 0 UTR, we hypothesize that AXL is a direct molecular target of miR-34a. miR-34a targets the 3 0 UTR of AXL to negatively affect luciferase reporter expression To test whether AXL contains a putative target site for miR34a, we used the full-length AXL 3 0 UTR as well as a more defined region of the UTR (48 bp representing nucleotides 18-65 from the start site of the 3 0 UTR; denoted as wildtype or WT) in a luciferase reporter expression system. We also created expression vectors containing base pair mutations within the putative seed sequence of this defined region to examine the specificity of this targeting interaction. In MDA-MB-231 cells, co-transfection of the fulllength 3 0 UTR of AXL with a siRNA (target site is within the AXL 3 0 UTR) results in a 97% loss of luciferase reporter expression (Fig. 2a) . On average, there was a 38% loss in luciferase expression with the 34a-mimic molecule (P \ 0.0001) but no significant change in luciferase expression with a miR-200c mimic. The miR-200c microRNA does not have a predicted target site within the AXL 3 0 UTR and therefore served as a negative control.
In assays involving a portion of the AXL 3 0 UTR that contains the putative target site for miR-34a, co-transfection of the WT vector with the 34a-mimic also resulted in an approximate 40% decrease in luciferase expression (Fig. 2b ), but this effect was nearly abolished when mutations in the putative seed sequence-binding regions were introduced. A single nucleotide alteration (M2 or M3; corresponding to nucleotide positions 2 and 3, respectively) in the seed sequence region was enough to produce the inhibitory effect.
miR-34a represses AXL at the transcriptional and translational level and has a downstream affect on AKT signaling in MDA-MB-231 cells Using MDA-MB-231 cells that were previously shown to be deficient in miR-34a, we examined the effects of ectopic miR-34a expression (in the form of a mimic molecule) on AXL mRNA and protein levels. Normalized AXL mRNA levels (relative to PPIB) were determined for each transfection condition using a branched DNA capture assay. As expected, when compared with negative control (siNEG) transfected cells, a loss of *80% in relative AXL mRNA levels was observed with a siRNA targeting AXL (Fig. 3a) . Surprisingly, transfections with the mimic molecule resulted in an approximate 60% decrease in relative AXL mRNA levels that was highly significant (P \ 0.0001). Similar effects were observed in the triple-negative breast cancer cell line Hs578T, in which there was an 86% loss in AXL mRNA levels with the siRNA and a 77% loss in AXL mRNA levels with the miR-34a mimic (Fig. 3a) . This decrease in AXL mRNA upon miR-34a overexpression, however, is consistent with recent reports suggesting mRNA degradation as the major component of mammalian miRNA-mediated gene regulation [50, 51] . For Hs578T cells, the effects of miR-34a on AXL mRNA levels may have been more pronounced as a result of lower endogenous AXL mRNA levels on average in these cells when compared to MDA-MB-231 cells.
At the protein level, the miR-34a mimic was effective in decreasing AXL protein by 90% compared to siNEG treated MDA-MB-231 cells (Fig. 3b) , whereas the receptor tyrosine kinase c-MET (a previously published target of miR-34a; see Refs. [22] [23] [24] [25] [26] [27] ) was decreased by only 30%. In comparison to negative control treated Hs578T cells, a 60% reduction in AXL protein levels was seen following transfection with the miR-34a mimic, but just a 30% decrease in c-MET levels (Fig. 3b) . These data suggest that in both MDA-MB-231 and Hs578T breast cancer cell lines, the affinity of AXL as a target for miR-34a appears to be greater than that of c-MET.
We also examined the downstream effects on AXL signaling when this gene is targeted for regulation by miR34a. One signaling network known to involve AXL is the PI3K/AKT effector pathway. Although there was not a significant change in PI3K phosphorylation (data not shown), there was an appreciable decrease in phospho- 
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Fig . 3 Ectopic miR-34a expression decreases AXL mRNA and protein levels with a downstream effect on AKT phosphorylation. a MDA-MB-231 or Hs578T cells transfected with either siAXL or a miR-34a mimic results in a significant decrease in AXL mRNA levels within these cells. AXL mRNA levels were normalized to PPIB for each transfected sample (data point). Horizontal bar represents the average signal ± SEM. b MDA-MB-231 or Hs578T cells transfected with either siAXL or a miR-34a mimic also results in a significant decrease in AXL protein levels. The receptor tyrosine kinase MET, which was previously shown to be a target for miR-34a, was also affected at the protein level but the results are not as dramatic as those seen with AXL. Values under each band represent the b-Actin normalized intensity of the band relative to that of the siNEG transfected sample. c Decreases in AXL protein levels by either siAXL or the miR-34a mimic affects AKT phosphorylation (at Thr308 and Ser473) in MDA-MB-231 cells with no decrease in total AKT levels. d The effects of siAXL and miR-34a on phospho-AKT (Thr308) are rescued with the co-transfection of an AXL expression vector that lacks the 3 0 UTR for targeting by these molecules. Western blots are representative of at least duplicate independent experiments AKT (both Thr308 and Ser473 residues) but not total AKT levels in cells transfected with either siAXL or the 34a-mimic (Fig. 3c) . We did not detect any noticeable changes in phospho-ERK1/2 (p42/p44 MAP kinase) and total ERK1/2 levels under these same transfections (data not shown).
More importantly, we conducted an AXL cDNA rescue experiment and observed the changes in phospho-AKT signaling (at the Thr308 residue). MDA-MB-231 cells cotransfected with an AXL cDNA expression vector lacking the 3 0 UTR sequence fully recovered AXL protein expression as the mRNA transcripts were not targeted by either the siRNA or the 34a-mimic (Fig. 3d) . This resulted in a recovery of phospho-AKT (Thr308) levels and supports the targeting influence miR-34a has on AXL.
AXL targeting by miR-34a results in impaired cell migration but has no significant effect on proliferation or cell cycle regulation
In previous studies, AXL was shown to have an active role in cellular migration for a variety of cell types including triple-negative breast cancer [20, 36, 37, [52] [53] [54] [55] . We examined the effects of miR-34a mediated knockdown of AXL protein levels on cell migration in both the MDA-MB-231 and Hs578T cell lines. MDA-MB-231 cells transfected with a miR-34a mimic resulted in a 37% decrease in migratory cells (P \ 0.001), whereas no effect on cell migration was observed in cells treated with an siRNA targeting c-MET (Fig. 4a) . The effect on cell migration was even more pronounced in Hs578T cells, as transfections with the miR-34a mimic resulted in a 53% decrease in migratory cells (Fig. 4b) . Interestingly, the si-MET transfection resulted in an overall increase in the number of migratory Hs578T cells that was statistically significant (P \ 0.001).
The reduced numbers in migratory cells upon transfection with the miR-34a mimic may be the result of impaired growth, proliferation, or even activation of cell death programming; and it may not necessarily reflect a single direct effect on decreased AXL levels within these cells. To determine whether the regulation of AXL by miR-34a principally alters the migration phenotype of MDA-MB-231 and Hs578T cells rather than alterations in cell growth and survival, we measured cell proliferation/viability and examined the cell cycle for growth arrest or induction of apoptosis in our transfected cells parallel to our migration assays. In MDA-MB-231 cells, we observed a modest decrease in cell viability (13%, P \ 0.05) for the miR-34a mimic transfection when using the CellTiter-BlueÒ Assay (Fig. 4c) . The observed results for the Hs578T cell line were very similar to that of MDA-MB-231. Transfection with the miR-34a mimic resulted in a 12% decrease in proliferative ability (P \ 0.0001) whereas transfection with an siRNA targeting c-MET increased the viability of the cells by *15% (Fig. 4d) . When comparing the various transfections in regard to cell-cycle analysis, the miR-34a mimic molecule did result on average in a 2.9% increase in the number of MDA-MB-231 cells in the G0/G1 phase with a concomitant decrease in cells entering the S-phase of the cell cycle when compared to siNEG transfected cells (Fig. 5a ). The Hs578T cell line also exhibited an increase in the number of cells that remained in the G0/G1 cell cycle (*5%) with a decrease in cells at the S-phase (Fig. 5b) . In a flow cytometric analysis with Annexin V staining as an indicator of apoptosis, there was a slight increase on average in early or pre-apoptotic MDA-MB-231 cells (compare lower right quadrants) for the siAXL, 34a-mimic, and siMET transfections (Fig. 6a) . We did not, however, observe a significant increase in the number of apoptotic cells (upper right quadrant) for each transfection compared to siNEG. Similarly, no significant change in the number of pre-apoptotic or apoptotic Hs578T cells (Fig. 6b) was observed with the 34a-mimic transfection compared to siNEG.
As AXL may not be the only miR-34a target with influence on cell migration, we conducted a global transcriptome profiling experiment on MDA-MB-231 cells transfected with either siNEG or the 34a-mimic to determine other contributing transcripts that might be affected.
Other than MET which also exhibited a -0.8 log 2 fold change, we did not observe downregulation of other computationally predicted targets of miR-34a with relevance to cell motility (e.g., RhoA, VCL, TBCA, TBCE, VASP, ANK2, and isoforms of MYO). Moreover, other than CCNE2, known miR-34a-targeted transcripts involved in cell-cycle regulation (e.g., CCND1, CDK6, and E2F3) were also not significantly affected. Overall, our results suggest that transfections with a miR-34a mimic did not cause a gross inhibitory effect on the viability or proliferative ability of these breast cancer cell lines, and that the observed negative effect of miR-34a expression on cell motility is most likely related to a decreased AXL protein expression in these cells.
miR-34a expression is inversely correlated with AXL mRNA expression in basal-like breast cancer tumor patient samples
We examined whether the expression of both miR-34a and AXL mRNA were correlated with one another in a clinically relevant setting by profiling the expression of these RNAs in 26 tumor samples from patients with basal-like breast cancer (Online Resource Table 4 ). Application of a nonparametric (Spearman) correlation analysis to the expression data (AXL mRNA normalized to b-actin and miR-34a normalized to RNU48) generated for all the 26 samples shows that AXL and miR-34a expression are inversely correlated with one another (r = -0.52; twotailed P \ 0.01) with significance ( Fig. 7) .
Discussion
The association of AXL expression with basal-like breast cancer was initially reported in a gene expression profiling study involving 51 independent breast cancer cell lines [6] ; but the factors contributing to this observation have not been thoroughly investigated. AXL expression as a result of discrete gene amplification or of amplification of its corresponding genomic region (19q13.1) resulting in copy number variations is not a common phenomenon identified in breast cancer. Furthermore, an actively mutated form of AXL is not hypothesized as there have been no reported somatic mutations within this gene in all primary breast carcinomas that have been examined (COSMIC Database) [56] . We hypothesized that AXL expression in triple-negative breast cancer is attributed to deregulation at the posttranscriptional level, possibly through the aberrant expression of a miRNA that targets AXL mRNA transcripts for sequestration or degradation.
In the present study, we demonstrate that the human miR-34a microRNA is significantly downregulated in expression in those highly invasive cell lines of the triplenegative histotype (MDA-MB-231, BT549, and Hs578T) that concomitantly exhibit high AXL protein expression. We showed that the 3 0 UTR of AXL contains a target site for miR-34a as ectopic expression of this miRNA resulted in loss of luciferase reporter expression as well as decreased endogenous AXL mRNA and protein levels. Phenotypically, targeting of AXL by miR-34a reduced phospho-AKT expression, and impaired the motility of triple-negative breast cancer cells toward a growth substrate, without having a significant affect on the viability of the cells. Furthermore, the miR-34a/AXL interaction appears clinically relevant, as there is an inverse correlation in expression for these molecules in basal-like breast cancer patient tumor samples.
The miR-34 family of microRNAs has garnered significant interest in tumor biology because its transcription is directly regulated by p53, and it participates in a functional role within this tumor suppressor pathway [41-44, 47, 48] . Several studies have shown that ectopic expression of miR34a can cause cell-cycle arrest in the G 1 phase [41, 44, 48] , cellular senescence [44] , and apoptosis [42, 47, 48, 57] . Several mRNA targets for miR-34a have been previously identified, and not surprisingly, a significant portion of them are known to be involved in cell-cycle control (for review see [58] ). Of the known mRNA targets for miR-34a, the proto-oncogenic hepatocyte growth factor receptor MET has been the most extensively studied to date because of its association in a wide variety of cancers [22] [23] [24] [25] [26] [27] . In our study, we compared the effects of miR-34a expression on both AXL and MET protein levels in two triple-negative breast cancer cell lines and we observed that the loss in protein translation was more pronounced for the receptor tyrosine kinase AXL than with MET. These results suggest that the functional consequence of miR-34a expression in tumor cells is highly dependent on the cell type and its cellular context. AXL mRNA and protein levels in triplenegative breast cancer cell lines are much more abundant than those of MET, and thus, the probability of targeting AXL over MET is greatly increased. In addition, the free energy of binding of miR-34a to AXL (DG = -28.5 kcal/ mol) is much lower than with MET (DG = -16.5 kcal/ mol), indicating that miR-34a has a greater likelihood of Open squares indicate those samples that were identified as having p53 mutations binding with AXL transcripts. We observed a similar phenomenon in regard to the effect of ectopic miR-34a expression on cell-cycle progression and apoptosis. Unlike the induction of apoptosis observed in neuroblastoma cell lines [57] , HCT116 p53 WT cells [42] , and H1299 and HEK293 cells [47, 48] ; miR-34a expression did not result in the induction of apoptosis in triple-negative breast cancer cell lines. Similarly, we did not observe a drastic increase in G 1 cell-cycle arrest unlike what has been previously reported for other cell lines [41, 44, 48] . We hypothesize that this observed difference reflects the presence of more abundant targets (e.g., AXL) within triplenegative breast cancer cell lines such that they are preferentially targeted minimizing the miR-34a effect on other targets involved in cell regulatory and survival pathways.
Recently, Mudduluru et al. have shown that miR-34a can regulate AXL expression and impair its functions that contribute to the migration, invasion, and formation of distant metastases of cancer cells [49] . AXL targeting by miR-34a was also confirmed through the application of in vitro assays using a modified method of mRNA pulldown and isolation with biotinylated miR-34a (Ashish Lal and Judy Lieberman, personal communication). In this article, we provide additional evidence for the targeting of AXL by miR-34a, and that this interaction (or lack thereof) is relevant to triple-negative breast cancer. The results of this study corroborates with the former and further substantiates AXL as second receptor tyrosine kinase to be identified as a target of miR-34a having similar pro-oncogenic properties to that of c-MET. As we continue to unravel the extent of the tumor suppressor role miR-34a plays in cells, it is reasonable to assume that one productive mechanism in shutting down the proliferative ability of cells would be to target the most upstream elements that are involved in growth factor binding and cellular signaling. Whether other receptor tyrosine kinases fall under the regulatory control of miR-34a awaits further experimentation.
